Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Study sponsor: IO Biotech
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-04-30Estimated
Enrollment · participants60Estimated
Source updated2024-03-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.